Counterpoint Mutual Funds LLC has acquired a new position in Lantheus Holdings, Inc., purchasing 1,300 shares valued at approximately $107,000. Lantheus Holdings, a medical equipment provider, reported better-than-expected financial performance in its most recent earnings report, with earnings per share of $1.37 and revenue of $300.78 million. Lantheus develops, manufactures, and commercializes diagnostic and therapeutic products that aid healthcare professionals in accurate diagnoses and effective treatments. Notable products offered by Lantheus include DEFINITY, TechneLite, Xenon-133, Neurolite, and Cardiolite. Despite a negative net margin, analysts have a positive outlook for Lantheus, predicting impressive earnings per share for the current fiscal year. Institutional investors, including National Bank of Canada FI, Wolverine Asset Management LLC, Coppell Advisory Solutions Corp., Globeflex Capital L P, and Shell Asset Management Co., have shown confidence in Lantheus by increasing their positions. Lantheus' stock performance has remained stable, with a one-year high of $100.85. Insider transactions by company executives also indicate their belief in the company's future prospects. Several research firms have provided positive reviews and increased their target prices for Lantheus. Overall, Lantheus Holdings is considered a promising investment option in the medical equipment sector.
Thu, 06 Jul 2023 01:43:51 GMT | Best Stocks